What is the prevalence of Acromicric Dysplasia?

Acromicric dysplasia is an extremely rare genetic disorder, with fewer than 50 cases documented in international medical literature to date. Because of its rarity and the potential for overlap with other skeletal dysplasias, its true prevalence remains unknown and it is classified as an ultra-rare condition.

How common is Acromicric dysplasia?

Acromicric dysplasia is considered an ultra-rare condition. Due to the limited number of reported cases, it is impossible to establish precise incidence or prevalence rates. While global registries like Orphanet recognize Acromicric dysplasia as a distinct entity, the lack of widespread population screening means that many individuals may remain undiagnosed or misdiagnosed as having more common forms of short-stature syndromes.

Is there a gender or ethnic bias in Acromicric dysplasia?

Current clinical data does not suggest that Acromicric dysplasia affects one gender more than the other, nor are there known geographic or ethnic clusters. The condition is typically identified in early childhood when significant growth delays and distinctive skeletal features become apparent. Because Acromicric dysplasia is caused by heterozygous mutations in the FBN2 gene, it follows an autosomal dominant inheritance pattern, meaning it can affect individuals regardless of their ancestry.

Why is accurate data for Acromicric dysplasia challenging to obtain?

Epidemiological tracking for Acromicric dysplasia faces several hurdles:

• Diagnostic overshadowing: Features of Acromicric dysplasia, such as short hands and feet, can be mistaken for other skeletal dysplasias.


• Under-reporting: Many cases may not be captured in medical literature, leading to an underestimation of the true global prevalence.


• Community perspective: While medical databases report low numbers, platforms like DiseaseMaps.org provide a crucial real-world view; currently, 3 individuals with Acromicric dysplasia have joined our community, highlighting the importance of patient-led data in rare disease research.

Next steps

• Consult with a clinical geneticist to discuss molecular testing for FBN2 mutations.


• Coordinate care with a pediatric endocrinologist to monitor growth and skeletal development.


• Connect with the DiseaseMaps.org community to share experiences and learn from others living with this rare condition.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Acromicric dysplasia (ORPHA:245)


• NIH GARD: Genetic and Rare Diseases Information Center - Acromicric dysplasia


• OMIM (Online Mendelian Inheritance in Man): #102370 - Acromicric dysplasia


• PubMed: Clinical and molecular characterization of patients with FBN2-related acromicric dysplasia.